# A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects

> **NCT04512872** · PHASE1 · COMPLETED · sponsor: **Celltrion** · enrollment: 30 (actual)

## Conditions studied

- Healthy Male Subjects

## Interventions

- **BIOLOGICAL:** CT-P41
- **BIOLOGICAL:** EU-approved Prolia

## Key facts

- **NCT ID:** NCT04512872
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-20
- **Primary completion:** 2021-05-04
- **Final completion:** 2021-05-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04512872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04512872, "A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04512872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*